Emerging Therapeutic Targets and Experimental Drugs for the Treatment of NAFLD

The two main subsets of nonalcoholic fatty liver disease (NAFLD) include: (1) nonalcoholic fatty liver (NAFL), the more common and non-progressive subtype; and (2) nonalcoholic steatohepatitis (NASH), the less common subtype, which has the potential to progress to advanced liver damage. Current trea...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Pratima Dibba, Andrew A. Li, Brandon J. Perumpail, Nimy John, Sandy Sallam, Neha D. Shah, Waiyee Kwong, George Cholankeril, Donghee Kim, Aijaz Ahmed
Format: Artigo
Langue:Inglês
Publié: MDPI AG 2018-09-01
Collection:Diseases
Sujets:
NAFLD
NASH
nonalcoholic fatty liver disease
drug therapy
chemokine receptor 2 and 5
galectin-3 protein
toll-like receptor 4
fibroblast growth factor 19
selective thyroid hormone receptor-beta
apoptosis signal-regulating kinase 1
acetyl-coenzyme A carboxylase
farnesoid X receptor
inflammasomes
Accès en ligne:http://www.mdpi.com/2079-9721/6/3/83
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires